Comparative aspects of the proliferation marker thymidine kinase 1 in human and canine tumour diseases

Veterinary and Comparative Oncology

Volumn 9, Issue 1, 2011, Pages 1-15

  Von Euler, H ^a   Eriksson, S ^a  

^a SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Comparative oncology; Dog; Human; Thymidine kinase 1; Tumour marker

Indexed keywords

THYMIDINE KINASE; THYMIDINE KINASE 1; TUMOR MARKER;

ANIMAL; ANIMAL DISEASE; BLOOD; BLOOD DISEASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CHEMISTRY; COMPARATIVE STUDY; DISEASE MODEL; DOG; DOG DISEASE; ENZYMOLOGY; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; REVIEW;

ANIMALS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOG DISEASES; DOGS; HEMATOLOGIC NEOPLASMS; HUMANS; NEOPLASMS; S PHASE; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL;

CANIS FAMILIARIS;

EID: 79551706824     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00238.x     Document Type: Review

References (77)

1. Bello LJ. Regulation of thymidine kinase synthesis in human cells. Experimental Cell Research 1974; 89: 263-274.
2. Topolcan O and Holubec L Jr. The role of thymidine kinase in cancer disease. Expert Opinion on Medical Diagnostics 2008; 2: 129-141.
3. Ellims PH, Eng Gan T, Medley G and Van Der Weyden MB. Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma. Blood 1981; 58: 926-930.
4. Kreis W, Arlin Z, Yagoda A, Leyland-Jones BR and Fiori L. Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease. Cancer Research 1982; 42: 2514-2517.
5. Gronowitz JS, Hagberg H, Kallander CF and Simonsson B. The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma. British Journal of Cancer 1983; 47: 487-495.
6. O'Neill KL, Abram WP and McKenna PG. Serum thymidine kinase levels in cancer patients. Irish Journal of Medical Science 1986; 155: 272-274.
7. Robertson JF, O'Neill KL, Thomas MW, McKenna PG and Blamey RW. Thymidine kinase in breast cancer. British Journal of Cancer 1990; 62: 663-667.
8. Eriksson S, Munch-Petersen B, Johansson K and Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cellular and Molecular Life Sciences 2002; 59: 1327-1346.
9. Dobrovolsky VN, Bucci T, Heflich RH, Desjardins J and Richardson FC. Mice deficient for cytosolic thymidine kinase gene develop fatal kidney disease. Molecular Genetics and Metabolism 2003; 78: 1-10.
10. Gasparri F, Wang N, Skog S, Galvani A and Eriksson S. Thymidine kinase 1 expression defines an activated G1 state of the cell cycle as revealed with site-specific antibodies and ArrayScan assays. European Journal of Cell Biology 2009; 88: 779-785.
11. Hengstschlager M, Knofler M, Mullner EW, Ogris E, Wintersberger E and Wawra E. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. The Journal of Biological Chemistry 1994; 269: 13836-13842.
12. Hu CM and Chang ZF. Mitotic control of dTTP pool: a necessity or coincidence? Journal of Biomedical Science 2007; 14: 491-497.
13. Welin M, Kosinska U, Mikkelsen NE, Carnrot C, Zhu C, Wang L, Eriksson S, Munch-Petersen B and Eklund H. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 17970-17975.
14. Kauffman MG and Kelly TJ. Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Molecular and Cellular Biology 1991; 11: 2538-2546.
15. Ke PY and Chang ZF. Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1- mediated pathway. Molecular and Cellular Biology 2004; 24: 514-526.
16. He Q, Skog S, Wang N, Eriksson S and Tribukait B. Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. European Journal of Cell Biology 1996; 70: 117-124.
17. Wu C, Yang R, Zhou J, Bao S, Zou L, Zhang P, Mao Y, Wu J and He Q. Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. Journal of Immunological Methods 2003; 277: 157-169.
18. O'Neill KL, Zhang F, Li H, Fuja DG and Murray BK. Thymidine kinase 1 - a prognostic and diagnostic indicator in ALL and AML patients. Leukemia 2007; 21: 560-563.
19. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T and Skog S. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncology Reports 2005; 14: 1013-1019.
20. Karlstrom AR, Neumuller M, Gronowitz JS and Kallander CF. Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA. Molecular and Cellular Biochemistry 1990; 92: 23-35.
21. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, Luthra SK, Brady F, Price PM and Aboagye EO. 3'-Deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Research 2003; 63: 3791-3798.
22. de Langen AJ, Klabbers B, Lubberink M, Boellaard R, Spreeuwenberg MD, Slotman BJ, de Bree R, Smit EF, Hoekstra OS and Lammertsma AA. Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 2009; 36: 389-395.
23. Shields AF, Mankoff DA, Link JM, Graham MM, Eary JF, Kozawa SM, et al. Carbon-11-thymidine and FDG to measure therapy response. Journal of Nuclear Medicine 1998; 39: 1757-1762.
24. Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N and Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. Journal of Nuclear Medicine 1992; 33: 1972-1980.
25. Yamada Y, Uchida Y, Tatsumi K, Yamaguchi T, Kimura H, Kitahara H and Kuriyama T. Fluorine-18-fluorodeoxyglucose and carbon-11-methionine evaluation of lymphadenopathy in sarcoidosis. Journal of Nuclear Medicine 1998; 39: 1160-1166.
26. Larson SM, Weiden PL, Grunbaum Z, Rasey JS, Kaplan HG, Graham MM, Harp GD, Sale GE and Williams DL. Positron imaging feasibility studies. I: Characteristics of [3H]thymidine uptake in rodent and canine neoplasms: concise communication. Journal of Nuclear Medicine 1981; 22: 869-874.
27. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, Obradovich JE, Muzik O and Mangner TJ. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Medicine 1998; 4: 1334-1336.
28. Nicolas F, De Sousa G, Thomas P, Placidi M, Lorenzon G and Rahmani R. Comparative metabolism of 3'-azido-3'-deoxythymidine in cultured hepatocytes from rats, dogs, monkeys, and humans. Drug Metabolism and Disposition 1995; 23: 308-313.
29. Ballegeer EA, Forrest LJ, Jeraj R, Mackie TR and Nickles RJ. PET/CT following intensity-modulated radiation therapy for primary lung tumor in a dog. Veterinary Radiology & Ultrasound 2006; 47: 228-233.
30. Salskov A, Tammisetti VS, Grierson J and Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine. Seminars in Nuclear Medicine 2007; 37: 429-439.
31. Dittmann H, Dohmen BM, Paulsen F, Eichhorn K, Eschmann SM, Horger M, Wehrmann M, Machulla HJ and Bares R. [18F]FLT PET for diagnosis and staging of thoracic tumours. European Journal of Nuclear Medicine and Molecular Imaging 2003; 30: 1407-1412.
32. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN and Hetzel M. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. Journal of Nuclear Medicine 2003; 44: 1426-1431.
33. Yamamoto Y, Nishiyama Y, Kimura N, Ishikawa S, Okuda M, Bandoh S, Kanaji N, Asakura M and Ohkawa M. Comparison of (18)F-FLT PET and (18)F-FDG PET for preoperative staging in non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging 2008; 35: 236-245.
34. Shields AF. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. Journal of Nuclear Medicine 2003; 44: 1432-1434.
35. Cobben DC, Elsinga PH, Hoekstra HJ, Suurmeijer AJ, Vaalburg W, Maas B, Jager PL and Groen HM. Is 18F-3'-fluoro-3'-deoxy-l-thymidine useful for the staging and restaging of non-small cell lung cancer? Journal of Nuclear Medicine 2004; 45: 1677-1682.
36. Apisarnthanarax S, Alauddin MM, Mourtada F, Ariga H, Raju U, Mawlawi O, Han D, Bornmann WG, Ajani JA, Milas L, Gelovani JG and Chao KS. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Clinical Cancer Research 2006; 12: 4590-4597.
37. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, Vogg AT, Mattfeldt T, Neumaier B, Moller P and Reske SN. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. European Journal of Nuclear Medicine and Molecular Imaging 2007; 34: 1775-1782.
38. Herrmann K, Wieder HA, Buck AK, Schoffel M, Krause BJ, Fend F, Schuster T, Meyer zum Buschenfelde C, Wester HJ, Duyster J, Peschel C, Schwaiger M and Dechow T. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine- positron emission tomography in high-grade non-Hodgkin's lymphoma. Clinical Cancer Research 2007; 13: 3552-3558.
39. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S and Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging 2007; 34: 1339-1347.
40. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME and Cloughesy T. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. Journal of Clinical Oncology 2007; 25: 4714-4721.
41. Kasper B, Egerer G, Gronkowski M, Haufe S, Lehnert T, Eisenhut M, Mechtersheimer G, Ho AD and Haberkorn U. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leukemia & Lymphoma 2007; 48: 746-753.
42. O'Neill KL, Hoper M and Odling-Smee GW. Can thymidine kinase levels in breast tumors predict disease recurrence? Journal of the National Cancer Institute 1992; 84: 1825-1828.
43. Spyratos F, Martin PM, Hacene K, Romain S, Andrieu C, Ferrero-Pous M, Deytieux S, Le Doussal V, Tubiana-Hulin M and Brunet M. Multiparametric prognostic evaluation of biological factors in primary breast cancer. Journal of the National Cancer Institute 1992; 84: 1266-1272.
44. Romain S, Martin PM, Klijn JG, van Putten WL, Look MP, Guirou O and Foekens JA. DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? International Journal of Cancer 1997; 74: 156-161.
45. Broet P, Romain S, Daver A, Ricolleau G, Quillien V, Rallet A, Asselain B, Martin PM and Spyratos F. Thymidine kinase as a proliferative marker: clinical relevance in 1, 692 primary breast cancer patients. Journal of Clinical Oncology 2001; 19: 2778-2787.
46. Romain S, Spyratos F, Guirou O, Deytieux S, Chinot O and Martin PM. Technical evaluation of thymidine kinase assay in cytosols from breast cancers. EORTC Receptor Study Group Report. European Journal of Cancer 1994; 30A: 2163-2165.
47. Romain S, Christensen IJ, Chinot O, Balslev I, Rose C, Martin PM and Thorpe SM. Prognostic value of cytosolic thymidine kinase activity as a marker of proliferation in breast cancer. International Journal of Cancer 1995; 61: 7-12.
48. Span P, Heuvel J, Romain S, Piffanelli A, Martin PM, Geurts-Moespot A and Sweep F. EORTC receptor and biomarker study group report analytical and technical evaluation of a thymidine kinase radio-enzymatic assay in breast cancer cytosols. Anticancer Research 2000; 20: 681-687.
49. Svobodova S, Topolcan O, Holubec L, Treska V, Sutnar A, Rupert K, Kormunda S, Rousarova M and Finek J. Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Research 2007; 27: 1907-1909.
50. Li HX, Lei DS, Wang XQ, Skog S and He Q. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer. Oncology Reports 2005; 13: 145-149.
51. Holschneider CH and Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Seminars in Surgical Oncology 2000; 19: 3-10.
52. Moore RG, MacLaughlan S and Bast RC Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecologic Oncology 2010; 116: 240-245.
53. Hallek M, Touitou Y, Levi F, Mechkouri M, Bogdan A, Bailleul F, Senekowitsch R and Emmerich B. Serum thymidine kinase levels are elevated and exhibit diurnal variations in patients with advanced ovarian cancer. Clinica Chimica Acta 1997; 267: 155-166.
54. Musto P, Bodenizza C, Falcone A, D'Arena G, Scalzulli P, Perla G, Modoni S, Parlatore L, Valvano MR and Carotenuto M. Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia. British Journal of Haematology 1995; 90: 125-130.
55. Sadamori N, Ikeda S, Yamaguchi K, Mine M, Hakariya S, Kinoshita H, Hayashi K, Nakamura T, Nagataki S and Ichimaru M. Serum deoxythymidine kinase in adult T-cell leukemia-lymphoma and its related disorders. Leukemia Research 1991; 15: 99-103.
56. Sadamori N. Clinical and biological significance of serum tumor markers in adult T-cell leukemia. Leukemia & Lymphoma 1996; 22: 415-419.
57. Votava T, Topolcan O, Holubec L Jr, Cerna Z, Sasek L, Finek J and Kormunda S. Changes of serum thymidine kinase in children with acute leukemia. Anticancer Research 2007; 27: 1925-1928.
58. Kallander CF, Simonsson B, Hagberg H and Gronowitz JS. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 1984; 54: 2450-2455.
59. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, Ostwald M, Busch R, Kuhn-Hallek I, Thiel E and Emmerich B. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999; 93: 1732-1737.
60. Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O'Brien S, Kantarjian H and Keating MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Annals of Oncology 2001; 12: 621-625.
61. Hallek M, Emmerich B, Strohmeyer S, Busch R, Reichle A and Senekowitsch R. Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors. Klinische Wochenschrift 1988; 66: 718-723.
62. Lehtinen T. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas. Cancer Detection and Prevention 1988; 12: 125-131.
63. Hallek M, Wanders L, Strohmeyer S and Emmerich B. Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Annals of Hematology 1992; 65: 1-5.
64. Rehn S, Gronowitz JS, Kallander C, Sundstrom C and Glimelius B. Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas. British Journal of Cancer 1995; 71: 1099-1105.
65. Poley S, Stieber P, Nussler V, Pahl H and Fateh-Moghadam A. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Anticancer Research 1997; 17: 3025-3029.
66. Öhrvik A, Lindh M, Einarsson R, Grassi J and Eriksson S. Sensitive nonradiometric method for determining thymidine kinase 1 activity. Clinical Chemistry 2004; 50: 1597-1606.
67. Chen Z, Zhou H, Li S, He E, Hu J, Zhou J and Skog S. Serological thymidine kinase 1 (STK1) indicates an elevated risk for the development of malignant tumours. Anticancer Research 2008; 28: 3897-3907.
68. He E, Xu XH, Guan H, Chen Y, Chen ZH, Pan ZL, Tang LL, Hu GZ, Li Y, Zhang M, Zhou J, Eriksson S, Fornander T and Skog S. Thymidine kinase1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung and esophagus cancer and non-Hodgking's lymphoma. Nucleoside, Nucleotides, Nucleic Acids 2010; 29: 352-359.
69. He Q, Zou L, Zhang PA, Lui JX, Skog S and Fornander T. The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody. The International Journal of Biological Markers 2000; 15: 139-146.
70. He Q, Fornander T, Johansson H, Johansson U, Hu GZ, Rutqvist LE and Skog S. Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer. Anticancer Research 2006; 26: 4753-4759.
71. Pan ZL, Ji XY, Shi YM, Zhou J, He E and Skog S. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. Journal of Cancer Research and Clinical Oncology 2010. [Epub ahead of print].
72. Greenlee PG, Filippa DA, Quimby FW, Patnaik AK, Calvano SE, Matus RE, Kimmel M, Hurvitz AI and Lieberman PH. Lymphomas in dogs. A morphologic, immunologic, and clinical study. Cancer 1990; 66: 480-490.
73. von Euler HP, Ohrvik AB and Eriksson SK. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs. Research in Veterinary Science 2006; 80: 17-24.
74. Nakamura N, Momoi Y, Watari T, Yoshino T, Tsujimoto H and Hasegawa A. Plasma thymidine kinase activity in dogs with lymphoma and leukemia. The Journal of Veterinary Medical Science 1997; 59: 957-960.
75. von Euler HP, Rivera P, Aronsson AC, Bengtsson C, Hansson LO and Eriksson SK. Monitoring therapy in canine malignant lymphoma and leukemia with serum thymidine kinase 1 activity - evaluation of a new, fully automated non-radiometric assay. International Journal of Oncology 2008; 34: 505-510.
76. von Euler H, Einarsson R, Olsson U, Lagerstedt AS and Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: a potent marker for prognosis and monitoring the disease. Journal of Veterinary Internal Medicine 2004; 18: 696-702.
77. Piek CJ, Rutteman GR and Teske E. Evaluation of the results of a l-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. The Veterinary Quarterly 1999; 21: 44-49.